Every 10-Q that Mannkind Corporation (MNKD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow MNKD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MNKD filings page.
MannKind Corporation reported net revenue of $109.4 million for the quarter ended June 30, 2026 and $199.5 million for the first six months of 2026, compared with $76.5 million and $154.9 million in the prior-year periods. Product sales, including Afrezza, V-Go and newly added Furoscix, totaled $127.5 million for the six months, while royalties from Tyvaso DPI contributed $65.1 million.
The company recorded a quarterly net loss of $19.0 million and a six‑month net loss of $35.7 million, versus net income of $0.7 million and $13.8 million a year earlier. Higher selling, general and administrative expense of $112.4 million, research and development of $35.2 million, amortization of acquired intangibles of $8.7 million and total interest expense of $27.3 million weighed on results. Net cash used in operating activities was $23.7 million for the six months.
As of June 30, 2026, cash, cash equivalents and restricted cash were $53.7 million, with additional short‑term investments of $58.2 million. Total liabilities were $799.5 million, including a $319.1 million term loan and liabilities related to the sale of future royalties and CVR contingent consideration, resulting in stockholders’ deficit of $67.2 million. United Therapeutics accounted for about 61% of consolidated revenues for both the three and six‑month periods. Following the 2025 scPharmaceuticals merger, the company recorded developed technology and IPR&D intangibles and goodwill, and achievement of CVR Milestone 1 in July 2026 will trigger an aggregate payout of approximately $44.8 million.
MannKind Corporation reported a net loss for the quarter ended March 31, 2026 despite higher revenue. Total revenues rose to $90.2 million from $78.4 million, driven by commercial product sales of $33.9 million, collaborations and services of $23.5 million, and royalties of $32.7 million.
Total expenses increased to $91.8 million, including higher research and development and selling, general and administrative costs, leading to a loss from operations of $1.7 million. After $14.7 million in net other expense, MannKind recorded a net loss of $16.6 million, or $0.05 per basic and diluted share. Cash, cash equivalents and restricted cash were $53.6 million, with total assets of $744.4 million and total liabilities of $803.6 million, resulting in stockholders’ deficit of $59.2 million.
MannKind Corporation reported Q3 2025 results with total revenue of $82,130,000, up from $70,079,000 a year ago. Net income was $7,985,000 (basic and diluted EPS $0.03), driven by higher product sales and royalties.
Revenue mix: product revenue $48,274,000, collaborations and services $26,506,000, and royalties $33,319,000. Operating income reached $18,896,000 as total expenses were $63,234,000. Other expense reflected an impairment of available-for-sale investment of $6,409,000.
On the balance sheet, cash and cash equivalents were $127,392,000 and short‑term investments were $132,643,000. A new term loan of $73,428,000 was outstanding. For the nine months, operating cash flow totaled $26,213,000. Stockholders’ deficit narrowed to $(44,552,000). After quarter end, MannKind completed the acquisition of scPharmaceuticals on October 7, 2025 following a $10,000,000 promissory note issued on August 24, 2025.